A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients
Lauren A. Byers(The University of Texas MD Anderson Cancer Center), David Ross Camidge(University of Colorado Anschutz Medical Campus)
Cited by 17
Related Papers
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis
|Oncogene|2016|215
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
|Cancer Cell|2024|154
The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers
|Oncogene|2015|128
Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer
|Clinical Cancer Research|2009|118